(Q38707737)

5 September 2017

1 reference

title

Nobel Lecture. The purine path to chemotherapy (English)

1 reference

5 September 2017

Elion GB

1

1 reference

5 September 2017

publication date

1 October 1989

1 reference

5 September 2017

1 reference

5 September 2017

volume

9

1 reference

5 September 2017

issue

5

1 reference

5 September 2017

page(s)

509-529

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01119794

5 September 2017

exact match

0 references

cites work

Metabolic Effects of Allopurinol and Allo-Xanthine

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Effects of allopurinol in relation to purine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Enzymatic and metabolic studies with allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Allopurinol in the prophylaxis of uric acid stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Antileishmanial effect of allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

The spectrum of antiviral activities of acyclovir in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

The biochemistry and mechanism of action of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Metabolism of acyclovir in virus-infected and uninfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Identification of small DNA fragments synthesized in herpes simplex virus-infected cells in the presence of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Acyclovir and Epstein--Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Acyclovir kinetics after intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

Effect of 6-mercaptopurine on antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01119794

21 January 2018

Identifiers

DOI

10.1007/BF01119794

1 reference

Dimensions Publication ID

5 September 2017

1033242390

0 references

1 reference